135276-48-1

Basic information

• Product Name: 2-acetylphenyl 4-fluorobenzoate
• Synonyms: 2-acetylphenyl 4-fluorobenzoate
• CAS NO: 135276-48-1
• Molecular Weight: 258.249
• Mol File: 135276-48-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-acetylphenyl 4-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-acetylphenyl 4-fluorobenzoate(135276-48-1)
• EPA Substance Registry System: 2-acetylphenyl 4-fluorobenzoate(135276-48-1)

Safety Data

• Hazardous Substances Data: 135276-48-1(Hazardous Substances Data)

Upstream product

• 405-99-2 para-fluorostyrene 
• 118-93-4 o-hydroxyacetophenone 
• 459-56-3 4-fluorobenzylic alcohol 
• 403-43-0 4-fluorobenzoyl chloride 

Downstream Products

• 1600504-72-0 tert-butyl 3-((1-(4-fluorophenyl)-9-oxo-2,9-dihydrochromeno[2,3-c]pyrrol-3-yl)methyl)-1H-indole-1-carboxylate 
• 1435773-71-9 tert-butyl 2-(1-(4-fluorophenyl)-9-oxo-2,9-dihydrochromeno[2,3-c]pyrrol-3-yl)acetate 
• 1645-21-2 2-(4-fluorophenyl)-4H-chromen-4-one 
• 899829-45-9 4'-fluoro-4-thioflavone 
• 135276-47-0 1-(4-fluorophenyl)-3-(2-hydroxyphenyl)propane-1,3-dione 

Relevant articles and documents

Copper-catalyzed chemoselective oxidative o-aroylation of 2-acetylphenols, alkyl salicylates and 1,3-dicarbonyl compounds using styrene derivatives

A novel copper-catalyzed chemoselective oxidative O-aroylation of 2-acetylphenols, alkyl salicylates and 1,3-dicarbonyl compounds with a wide range of styrene derivatives are described. This approach provides an efficient chemoselective preparation of phenol, alkyl salicylate and enol esters in good to excellent yields. This method represents an alternative protocol for the classical esterification reactions.

Design, synthesis and biological evaluation of 2-Phenyl-4H-chromen-4-one derivatives as polyfunctional compounds against Alzheimer’s disease

Polyfunctional compounds comprise a novel class of therapeutic agents for the treatment of multi-factorial diseases. A series of 2-Phenyl-4H-chromen-4-one and its derivatives (5a–n) were designed, synthesized, and evaluated for their poly-functionality against acetylcholinestrase (AChE) and advanced glycation end products (AGEs) formation inhibitors against Alzheimer’s disease (AD). The screening results showed that most of them exhibited a significant ability to inhibit AChE AGEs formation with additional radical scavenging activity. Especially, 5m, 5b, and 5j displayed the greatest ability to inhibit AChE (IC50 = 8.0, 8.2, and 11.8 nM, respectively) and AGEs formation (IC50 = 55, 79, and 54 μM, respectively) with good antioxidant activity. Molecular docking studies explored the detailed interaction pattern with active, peripheral, and mid-gorge sites of AChE. These compounds, exhibiting such multiple pharmacological activities, can be further taken a lead for the development of potent drugs for the treatment of Alzheimer’s disease.

Aldose reductase inhibitors for diabetic complications: Receptor induced atom-based 3D-QSAR analysis, synthesis and biological evaluation

Herein, atom-based 3D-QSAR analysis was performed using receptor-guided alignment of 46 flavonoid inhibitors of aldose reductase (ALR2) enzyme. 3D-QSAR models were generated in PHASE programme, and the best model corresponding to PLS factor four (QSAR4), was selected based on different statistical parameters (i.e., Rtrain2, 0.96; Qtest2 0.81; SD, 0.26). The contour plots of different structural properties generated from the selected model were utilized for the designing of five new congener molecules. These designed molecules were duly synthesized, and evaluated for their in vitro ALR2 inhibitory activity that resulted in the micromolar (IC50 22 μM) activity of all molecules. Thus, the newly designed molecules having ALR inhibitory potential could be employed for the management of diabetic complications.